To investigate the clinical relevance of ABCB1 expression status depending on the type of TP53 mutations with progression free survival (PFS) rates mediated by acquired resistance to platinum-based drugs in patients with ovarian cancer, we assessed the data from human serous ovarian carcinoma samples in the cBioPortal and COSMIC databases for molecular alterations, gene expression, and treatment history with PFS [27–29]. This evidence concerns the gene TP53 and ovarian carcinoma.